Telix Pharmaceuticals Announces Publication Of Results From The ProstACT SELECT Study In Cancers, A Peer-Reviewed Journal; Peer-Reviewed Publication of ProstACT SELECT1 Results Confirm The Utility Of 68Ga -PSMA-PET Imaging To Select Patients For TLX591-Tx Therapy Using A Theranostic Approach

Loading news article.

Telix Pharmaceuticals Announces Publication Of Results From The ProstACT SELECT Study In Cancers, A Peer-Reviewed Journal; Peer-Reviewed Publication of ProstACT SELECT1 Results Confirm The Utility Of 68Ga -PSMA-PET Imaging To Select Patients For TLX591-Tx Therapy Using A Theranostic Approach | WAPE

Telix Pharmaceuticals Announces Publication Of Results From The ProstACT SELECT Study In Cancers, A Peer-Reviewed Journal; Peer-Reviewed Publication of ProstACT SELECT1 Results Confirm The Utility Of 68Ga -PSMA-PET Imaging To Select Patients For TLX591-Tx Therapy Using A Theranostic Approach

Article summary

Related companies

Comments —